Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.

Upon statistical normalization of the TG levels using logarithmic transformation, due to the wide baseline range (Figure 3A ), a highly significant decrease was observed following administration of aleglitazar (Figure 3B ; P = 0.0048).

also in 132,142 other papers